We simply cannot express the strength of our gratitude for everyone who participated in the Myotonic Dystrophy Foundation (MDF) 2020 Virtual Gala! We are truly blown away by the incredible outpouring of generosity and support.
MDF is excited to share that Avidity Biosciences' Phase 1/2 MARINATM study of AOC 1001 is now dosing adults living with myotonic dystrophy type 1! This is a significant step forward for DM drug development and marks the first time a person has been dosed with an Antibody Oligonucleotide Conjugate (AOC).
The Virtual Support Group Meeting for Adults Over 50 Living with DM1 had its inaugural launch on Sunday, November 14th.
August 4, 2021. Worldwide: The Myotonic Dystrophy Foundation (MDF) applauds U.S. Senator Tim Kaine (D-VA) for introducing the first ever U.S. Senate resolution designating September 15th as International Myotonic Dystrophy Awareness Day.